Debt-to-equity of X4 Pharmaceuticals, Inc from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
X4 Pharmaceuticals, Inc quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • X4 Pharmaceuticals, Inc Debt-to-equity for the quarter ending 30 Sep 2025 was 393%, a 83% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

X4 Pharmaceuticals, Inc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 393% +178% +83% 30 Sep 2025
Q2 2025 415% +215% +107% 30 Jun 2025
Q1 2025 234% +10% +4.6% 31 Mar 2025
Q4 2024 265% +105% +66% 31 Dec 2024
Q3 2024 214% +74% +53% 30 Sep 2024
Q2 2024 200% +78% +64% 30 Jun 2024
Q1 2024 224% +106% +90% 31 Mar 2024
Q4 2023 160% +51% +47% 31 Dec 2023
Q3 2023 140% +41% +41% 30 Sep 2023
Q2 2023 122% +26% +27% 30 Jun 2023
Q1 2023 118% +41% +54% 31 Mar 2023
Q4 2022 108% +44% +67% 31 Dec 2022
Q3 2022 100% +37% +59% 30 Sep 2022
Q2 2022 97% +40% +71% 30 Jun 2022
Q1 2022 77% +27% +54% 31 Mar 2022
Q4 2021 65% +22% +51% 31 Dec 2021
Q3 2021 62% +29% +87% 30 Sep 2021
Q2 2021 56% +25% +81% 30 Jun 2021
Q1 2021 50% +18% +57% 31 Mar 2021
Q4 2020 43% +3% +8.5% 31 Dec 2020
Q3 2020 33% -63% -65% 30 Sep 2020
Q2 2020 31% +658% 30 Jun 2020
Q1 2020 32% +85% 31 Mar 2020
Q4 2019 40% +71% 31 Dec 2019
Q3 2019 96% +133% 30 Sep 2019
Q2 2019 -626% 30 Jun 2019
Q1 2019 -54% 31 Mar 2019
Q4 2018 -32% 31 Dec 2018
Q3 2018 -37% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.